MedTrace Logo

Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

NCT03480698 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1851

Last updated 2025-02-25

No results posted yet for this study

Summary

This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Cerebrolysin

Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.

Sponsors & Collaborators

  • IDV Data analysis and study planning Dr. Rahlfs

    collaborator UNKNOWN

  • Ever Neuro Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Michael Brainin, Univ.-Prof. Dr. · Danube University Krems - Head of the Department for Clinical Neuroscience and Preventive Medicine / Head of the Center for Neurosciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-24
Primary Completion
2024-04-30
Completion
2024-07-15

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480698 on ClinicalTrials.gov